Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Psychosis in Parkinson's disease: therapeutic options.

Hasnain M.

Drugs Today (Barc). 2011 May;47(5):353-67. doi: 10.1358/dot.2011.47.5.1584113. Review.

PMID:
22013566
2.

Treatment of psychosis in Parkinson's disease: safety considerations.

Fernandez HH, Trieschmann ME, Friedman JH.

Drug Saf. 2003;26(9):643-59. Review.

PMID:
12814332
3.

Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Zahodne LB, Fernandez HH.

Drugs Aging. 2008;25(8):665-82. Review.

4.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

5.

[Clozapine for the treatment of psychosis in 3 elderly patients with Parkinson's disease].

Diraoui S, van Melick EJ, Jansen PA.

Ned Tijdschr Geneeskd. 2004 Nov 27;148(48):2365-8. Dutch.

PMID:
15615268
6.

[Drug treatment of dementia with Lewy bodies and Parkinson's disease dementia--common features and differences].

Drach LM.

Med Monatsschr Pharm. 2011 Feb;34(2):47-52; quiz 53-4. Review. German.

PMID:
21428015
7.

Evidence-Based Review of Pharmacotherapy Used for Parkinson's Disease Psychosis.

Wilby KJ, Johnson EG, Johnson HE, Ensom MHH.

Ann Pharmacother. 2017 Aug;51(8):682-695. doi: 10.1177/1060028017703992. Epub 2017 Apr 6. Review.

PMID:
28385039
8.

Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease.

Friedman JH, Factor SA.

Mov Disord. 2000 Mar;15(2):201-11. Review.

PMID:
10752567
9.

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.

Friedman JH, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J, Carson WH, Marcus RN.

Mov Disord. 2006 Dec;21(12):2078-81.

PMID:
17013906
10.

Atypical antipsychotic drugs in the treatment of Parkinson's disease.

Friedman JH.

J Pharm Pract. 2011 Dec;24(6):534-40. doi: 10.1177/0897190011426556. Epub 2011 Nov 17. Review.

PMID:
22095576
11.

Atypical antipsychotics for psychosis in adolescents.

Kumar A, Datta SS, Wright SD, Furtado VA, Russell PS.

Cochrane Database Syst Rev. 2013 Oct 15;(10):CD009582. doi: 10.1002/14651858.CD009582.pub2. Review.

PMID:
24129841
12.

Treatment options for depression and psychosis in Parkinson's disease.

Poewe W, Seppi K.

J Neurol. 2001 Sep;248 Suppl 3:III12-21. Review.

PMID:
11697683
13.

Olanzapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review.

14.

Clozapine and risperidone treatment of psychosis in Parkinson's disease.

Ellis T, Cudkowicz ME, Sexton PM, Growdon JH.

J Neuropsychiatry Clin Neurosci. 2000 Summer;12(3):364-9.

PMID:
10956570
15.

Novel pharmaceuticals in the treatment of psychosis in Parkinson's disease.

Broadstock M, Ballard C, Corbett A.

Expert Rev Clin Pharmacol. 2014 Nov;7(6):779-86. doi: 10.1586/17512433.2014.966814. Epub 2014 Oct 10. Review.

PMID:
25301532
16.

Quetiapine (Seroquel) in the treatment of psychosis in patients with Parkinson's disease.

Parsa MA, Bastani B.

J Neuropsychiatry Clin Neurosci. 1998 Spring;10(2):216-9.

PMID:
9608412
17.

Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis.

Frieling H, Hillemacher T, Ziegenbein M, Neundörfer B, Bleich S.

Eur Neuropsychopharmacol. 2007 Feb;17(3):165-71. Epub 2006 Oct 27. Review.

PMID:
17070675
18.

Olanzapine for the treatment of psychosis in patients with Parkinson's disease and dementia.

Marsh L, Lyketsos C, Reich SG.

Psychosomatics. 2001 Nov-Dec;42(6):477-81.

PMID:
11815682
19.

The Efficacy and Safety of Antipsychotic Medications in the Treatment of Psychosis in Patients with Parkinson's Disease.

Divac N, Stojanović R, Savić Vujović K, Medić B, Damjanović A, Prostran M.

Behav Neurol. 2016;2016:4938154. doi: 10.1155/2016/4938154. Epub 2016 Jul 18. Review.

20.

An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.

Krzystanek M, Krupka-Matuszczyk I.

Hum Psychopharmacol. 2011 Jan;26(1):81-5. doi: 10.1002/hup.1173. Epub 2011 Feb 9. Review.

PMID:
23055416

Supplemental Content

Support Center